MedTrace Logo

Defining 'Normal' Liver Function Tests & FibroScan Values in Pregnancy

NCT03883789 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2019-03-21

No results posted yet for this study

Summary

The main aim of this single-site prospective study is to use serum liver function tests and FibroScan as assessment tools to measure liver disease in pregnant women with or without liver disease at King's College Hospital. This will be assessed during each trimester of pregnancy. FibroScan will assess liver stiffness in these participants and will be used as a surrogate marker for fibrosis.

Conditions

Interventions

DIAGNOSTIC_TEST

FibroScan

FibroScan will be used to assess liver stiffness

Sponsors & Collaborators

  • King's College Hospital NHS Trust

    lead OTHER

Principal Investigators

  • Mussarat N Rahim, MBBSBScMRCP · King's College Hospital NHS Trust

Eligibility

Min Age
16 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2020-10-01
Completion
2020-11-01
FDA Device
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03883789 on ClinicalTrials.gov